Navigation Links
Vermillion Sharpens Focus and Streamlines Operations in 2012
Date:1/4/2012

ding the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.

 

 

 


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
2. Vermillion Reports Results for the Second Quarter 2011
3. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
4. Vermillion Announces Joining Russell Microcap® Index
5. Vermillion Announces Notice of Allowance for Alzheimer Patent
6. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
7. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
8. Stephens Initiates Coverage on Vermillion
9. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
10. Vermillion Announces Issuance of European Patent
11. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( ... Orthopedics, announced today the acquisition of Turner Medical, Inc ., thus becoming ... instruments to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... Wilmington, DE (PRWEB) , ... July 01, 2015 , ... ... to develop new ideas to lower the barriers to innovation in life sciences R&D. ... for up to two cash prizes of US$15,000 and a period of expert mentorship ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... of California, Berkeley, researchers have taken genes from grass-eating fungi ... from tough plant material cellulose that normal yeast ... the biofuels industry, which is struggling to make cellulosic ethanol ... economically feasible. "By adding these genes to yeast, ...
... available in German . , Behind every coincidence ... least. In principle, every event, including the fall of dice or ... mathematical terms. Researchers at the Max Planck Institute for the Physics ... the principle of true randomness. With the help of quantum physics, ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, announced today that Dr. Arthur ... present at the Stifel Nicolaus Healthcare Conference in Boston ... Time. A live webcast of the presentation ...
Cached Biology Technology:Researchers expand yeast's sugary diet to include plant fiber 2Researchers expand yeast's sugary diet to include plant fiber 3Researchers expand yeast's sugary diet to include plant fiber 4Random numbers game with quantum dice 2Random numbers game with quantum dice 3Random numbers game with quantum dice 4Lexicon to Present at Stifel Nicolaus Healthcare Conference 2
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... once thought to lie outside the reach of science, ... Medical Center have captured and sequenced tiny pieces of ... protein fragments—seven in all—appear to most closely match amino ... lending support to a recent and still controversial proposal ...
... study by researchers led by Kurt Kroenke, M.D., of the ... reports that nearly 20 percent of patients seen by primary ... outlines the effectiveness of a new screening tool which can ... or more anxiety disorders. The study is published in ...
... the genome sequence of the rhesus macaque monkey and ... April 13 in a special section of the journal ... share about 93 percent of their DNA, yet have ... paper, the Rhesus Macaque Genome Sequence and Analysis Consortium, ...
Cached Biology News:Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 2Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 4Anxiety disorders surprisingly common yet often untreated 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: